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A B S T R A C T
Purpose: This study explored the pharmacodynamic and pharmacokinetic effects of combining
perampanel (PER) with commonly co-administered AEDs.
Method: A strong stimulus intensity (three-fold higher than after-discharge threshold) was used to elicit
drug-resistant seizures in a rat amygdala kindling model. Vehicle, low-dose PER (0.75 mg/kg), or high-
dose PER (1.5 mg/kg), in combination with vehicle, levetiracetam (LEV) 50 mg/kg, lamotrigine (LAM)
20 mg/kg, carbamazepine (CBZ) 20 mg/kg, or valproic acid (VPA) 200 mg/kg, were administered
intraperitoneally to groups of 6–13 rats. Seizure score, electroencephalography (EEG) seizure duration,
and motor seizure duration were evaluated, with pharmacodynamic interactions determined by two-
way analysis of variance (ANOVA). Motor impairment was evaluated by rotarod test and two-way
ANOVA.
Results: High-dose PER, but not low-dose PER, LEV, LAM, CBZ, or VPA, reduced EEG seizure duration,
motor seizure duration, and seizure score compared with vehicle alone. However, when low-dose PER
was administered in combination with LEV, LAM, CBZ, or VPA, seizure severity parameters were reduced
compared with the concomitant AEDs alone. These pharmacodynamic interactions were statistically
signiﬁcant in some cases, but the same AED combinations were not associated with statistically
signiﬁcant neurotoxic interactions. Efﬁcacy may have been slightly affected by changes in PER plasma
concentrations in the presence of other AEDs:PER plasma concentrations increased with LEV or LAM
co-administration, and decreased with CBZ or VPA co-administration.
Conclusion: Overall, these data support published Phase III data demonstrating the efﬁcacy of PER as
adjunctive therapy for the treatment of refractory partial-onset seizures in patients aged 12 years.
 2014 The Authors. Published by Elsevier Ltd. This is an open access article under the CC BY-NC-ND
license (http://creativecommons.org/licenses/by-nc-nd/3.0/).
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It has been estimated that 20–40% of patients with epilepsy will
experience partial-onset seizures that are refractory to current
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3.0/).implemented, clinical studies have provided limited data to guide
the appropriate and effective combination of antiepileptic drugs
(AEDs), and currently administered combinations tend to be
selected based on their potential for minimal pharmacokinetic or
pharmacodynamic interactions rather than their clinical efﬁcacy.2
The development of rational combination therapies may be
facilitated by the identiﬁcation of AEDs with discrete mechanisms
of action and well-established pharmacodynamic proﬁles.
Perampanel (PER), a noncompetitive a-amino-3-hydroxy-5-
methyl-4-isoxazole-propionic acid (AMPA) receptor antagonist, is
a structurally novel, ﬁrst-in-class AED that is approved in the USA
and Europe for the adjunctive treatment of refractory partial-onset
seizures in patients aged 12 years.3,4 The perampanel approvals
were based on efﬁcacy and safety data from three Phase III
registration trials.5–7 In a pooled analysis of pharmacokinetic ande under the CC BY-NC-ND license (http://creativecommons.org/licenses/by-nc-nd/
T. Wu et al. / Seizure 23 (2014) 732–739 733pharmacodynamic data from the registration trials, a signiﬁcant
relationship was shown to exist between increases in PER plasma
concentration (i.e., systemic exposure) and reductions in seizure
frequency.8
The discrete mechanism of action of PER may be expected to
complement the mechanism of action of other currently available
AEDs.9,10 In the Phase III trials, PER efﬁcacy appeared consistent
across subgroups of patients receiving any of the four most
commonly administered concomitant AEDs (i.e., levetiracetam
[LEV], lamotrigine [LAM], carbamazepine [CBZ], and valproic acid
[VPA]).11 However, it is important to note that 86% of patients were
receiving at least two concomitant AEDs, which may have included
enzyme-inducing AEDs.11 Consequently, such polytherapy, as well
as the complexity of epilepsy, make it difﬁcult to estimate
pharmacodynamic interactions between PER and speciﬁc AEDs in
this clinical setting. A clearer picture may be provided by
preclinical studies, where variables can be manipulated in an
experimental system.12
The rat amygdala kindling model, an experimental system in
which the number of repeated brief seizures can be controlled,
allows investigation of the progressive nature of epilepsy.12 As
the animals exhibit a plethora of molecular, cellular, and
network alterations reﬂecting those reported in patients, the
model is clinically relevant for investigating the effect of treatment
with concomitant AEDs on refractory partial-onset seizures.
Historically, experience with various AEDs has supported the
predictive validity of the amygdala kindling model for the
treatment of focal and generalized tonic–clonic seizures in
the clinical setting.13 Seizures induced in the amygdala kindling
model by a strong stimulus intensity are associated with reduced
AED efﬁcacy and may, therefore, provide a suitably sensitive model
for assessing the pharmacodynamic interactions of AEDs.14,15
Here, a drug-resistant rat amygdala kindling model was used to
explore interactions between PER and the four most commonly co-
administered AEDs in the Phase III registration trials (LEV, LAM,
CBZ, and VPA), by studying the effects of combinations of these
AEDs on seizure score, electroencephalography (EEG) seizure
duration, motor seizure duration, neurotoxicity and plasma AED
concentrations.
2. Materials and methods
2.1. Animals
Male Wistar Kyoto rats (Charles River Laboratories Japan Inc.,
Kanagawa, Japan), weighing 250–400 g were used for all experi-
ments. Animals were housed in cages in a controlled environment
(constant temperature 22  1 8C; humidity 50–60%; 12-h dark/light
cycle [lights on between 07:00 and 19:00]) and had free access to food
(MF; Oriental Yeast Co., Tokyo, Japan) and water. All animal
experiments were approved by the Committee for the Welfare of
Laboratory Animals of Eisai Co. Ltd.
2.2. Stereotaxic surgery
Animals were acclimatized for at least 1 week prior to surgery.
On the day of surgery, rats were anesthetized with pentobarbital
65 mg/kg (Somnopentyl; Kyoritsu Seiyaku Co. Ltd, Tokyo, Japan)
administered intraperitoneally (i.p.). A tripolar electrode (TN201-
059; Unique Medical Co. Ltd, Tokyo, Japan) was implanted into the
basolateral amygdala (anterior–posterior: 2.5 mm; lateral:
4.8 mm; depth: 7.5 mm) according to the coordinates of
Paxinos and Watson.16 A reference electrode was placed on the
contralateral cortex. Electrodes were ﬁxed to the skull with acrylic
dental cement. After electrode implantation, rats were returned to
their home cage and allowed to recover.2.3. Amygdala kindling
After at least 1 week of recovery, the after-discharge
threshold (ADT) was determined for each rat. To achieve this,
the rat amygdala was stimulated using an electronic stimulator
(SEN-7203, Nihon Kohden, Tokyo, Japan) and the following
parameters: 500 mA, 1 ms, monophasic square-wave pulses, 50/
s for 1 s. Stimulation was initiated at 0.04 mA and was then
increased by 25% every 30 s until the ADT was elicited. The ADT
was deﬁned as the point when abnormal EEG, and a behavioral
seizure of at least Racine stage-1, was observed. Racine seizure
stage was classiﬁed as follows: (1) mouth and facial move-
ments; (2) head nodding; (3) unilateral forelimb clonus; (4)
rearing and bilateral forelimb clonus; and (5) rearing and
falling.
2.4. Drugs
PER (Eisai Co. Ltd, Tokyo, Japan), LEV (Tokyo Chemical Industry
Co. Ltd, Tokyo, Japan), LAM (AK Scientiﬁc Inc., California, USA), CBZ,
and VPA (Wako Pure Chemical Industries, Ltd, Tokyo, Japan) were
dissolved in a 1:1:1 mixture of water, dimethyl sulfoxide, and
polyethylene glycol-200 (hereafter denoted as vehicle). Drugs
were administered intraperitoneally 30 min (PER, LEV, CBZ, VPA)
or 60 min (LAM) prior to ADT evaluation.
2.5. Dose selection
The effects of PER 0–1.5 mg/kg, LEV 0–50 mg/kg, LAM 0–20 mg/
kg, CBZ 0–30 mg/kg, and VPA 0–400 mg/kg on ADT were assessed
in groups of 5–13 rats. Mean changes in ADT were compared with
pretreatment data using one-way analysis of variance (ANOVA),
followed by Dunnett’s multiple comparison test (signiﬁcance level
p < 0.05). Doses that signiﬁcantly elevated ADT were selected for
use in the subsequent analyses.
2.6. Pharmacodynamic interaction analyses
Seizures induced by high-intensity stimuli (three-fold higher
than the ADT stimulus [3ADT]) were used to establish a drug-
resistant amygdala kindling model. This intensity of stimulation
was selected to increase the sensitivity of the study, as
some AEDs begin to lose anti-seizure effects at this high
intensity.17
Effects of individual AEDs and combinations of AEDs on
Racine seizure score,18 EEG seizure duration (duration from start
of spiking EEG activity to the end of continuous spiking activity),
and motor seizure duration (duration of Racine score 4–5
seizures) were evaluated using the 3ADT-stimulus rat amygdala
kindling model in groups of four to eight rats per treatment
group (crossover between treatment groups led to actual sample
sizes of 8–38 rats). Mean seizure score was presented as a score
ranging from 0 to 5 (0, no seizure behavior; 5, full motor
seizure); mean EEG seizure duration and motor seizure duration
were presented as percentages of pretreatment values.
For the effects of individual AEDs, changes in seizure
parameters from pretreatment were analyzed using a one-way
ANOVA (signiﬁcance level p < 0.05).
To explore the pharmacodynamic interactions of LEV, LAM, CBZ,
or VPA when combined with vehicle, low-dose PER, or high-dose
PER, a non-parametric Steel-Dwass test was used to compare
seizure score, and a parametric Tukey’s multiple comparison test
was used to compare EEG seizure duration and motor seizure
duration (signiﬁcance level p < 0.05).
In addition, the same data set was analyzed for pharmacody-
namic interactions between PER and the other AEDs using a
Table 1
Effects of individual AEDs on ADT in the rat amygdala kindling model.
Drug Dose, mg/kg Mean percentage increase
in ADT compared with
pretreatment (SEM)
PER (n = 5–8) 0 (vehicle only) 104.4 (4.0)
0.4 109.6 (6.1)
0.7 152.1 (22.0)
1.5 225.6 (41.4)a
LEV (n = 12–13) 0 (vehicle only) 94.3 (3.0)
12.5 115.0 (6.1)
25 124.1 (7.9)a
50 132.5 (11.1)a
LAM (n = 8) 0 (vehicle only) 97.5 (6.2)
5 112.5 (4.4)
10 140.5 (8.0)a
20 148.8 (8.6)a
CBZ (n = 10–11) 0 (vehicle only) 97.8 (2.2)
10 128.5 (5.4)a
30 143.4 (10.0)a
VPA (n = 8) 0 (vehicle only) 100.0 (4.7)
100 138.0 (7.4)
200 188.5 (17.5)a
400 219.0 (21.1)a
ADT, after-discharge threshold; AED, antiepileptic drug; CBZ, carbamazepine; LAM,
lamotrigine; LEV, levetiracetam; PER, perampanel; SEM, standard error of the
mean; VPA, valproic acid.
a p < 0.05 vs pretreatment.
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perampanel (analysis not speciﬁc to low or high dose), and each
concomitant AED, to be evaluated as part of the combination, such
that the contribution of each AED to the overall anti-seizure effects
could be analyzed. A non-parametric ANOVA was used to analyze
effects on seizure score, while a parametric ANOVA was used to
analyze effects on EEG seizure duration and motor seizure
duration. If positive interactions were statistically signiﬁcant
(signiﬁcance level p < 0.05), with greater effects than the sum of
the effects achieved with the individual AEDs, then the interactions
were deﬁned as signiﬁcant. Alternatively, if interactions were
associated with similar, or almost similar, effects compared with
the sum of those achieved with the individual AEDs, then the
interactions were considered non-signiﬁcant.
2.7. Rotarod test
A rotarod test was performed to explore the potential for motor
impairment, as a form of neurotoxicity, when animals were treated
with low-dose PER, LEV, LAM, CBZ, or VPA, alone or in combination.
Rats were introduced to the rotating rod during a three-day
training period. On the day of testing, rats were placed on a rod
with a constant rotating speed of 6 rpm, and the baseline time to
fall for each animal was averaged over two attempts (cut-off:
120 s); those who remained on the rod for a mean time of >90 s
were used for the test. During the test, AEDs were administered
as previously described to groups of six rats. Twenty minutes
after administration, the rats were placed on a rod with a
constant rotating speed of 6 rpm and the latency time to fall was
recorded.
The effects of individual treatment with low-dose PER, LEV,
LAM, CBZ, or VPA were analyzed using Dunnett’s multiple
comparisons (signiﬁcance level p < 0.05). A two-way ANOVA
was used to assess the interaction of low-dose PER with the other
AEDs (signiﬁcance level p < 0.05).
2.8. Plasma concentrations and pharmacokinetic analyses
Groups of four rats each were treated with low-dose PER, LEV,
LAM, CBZ, or VPA plus vehicle, or combinations of low-dose PER
with each of the other four AEDs. Plasma samples were obtained
from each animal, deproteinized with acetonitrile and ﬁltered.
They were then diluted 20-fold with 50% acetonitrile and
concentrations were analyzed using a Waters LC/MS/MS system
(Waters Co., MA, USA).
For PER, LEV, LAM, and CBZ, ionization mode was positive
electrospray ionization. Chromatography was performed using a
Chromolith1FastGradient RP-18e (2.0 mm i.d.  50 mm; Merck,
Darmstadt, Germany). The mobile phases were: (A) water
containing 0.1% formic acid; (B) acetonitrile containing 0.1%
formic acid. The initial condition was (A) 100%, and (B) was
increased linearly to 50% or 80% over 3 minutes. The monitoring
ions were: PER, 350.2/219.3; LEV, 170.9/126.0; LAM, 256.0/108.9;
and CBZ, 237.3/194.0. Flow rate was 0.3 mL/min.
For VPA, ionization mode was negative electrospray ionization.
Chromatography was performed using LUNA 5u C18(2) 100 A˚
(2.0 mm i.d.  50 mm; Phenomenex, California, USA). The mobile
phases were: (A) 1 mol/L ammonium acetate/water (1:200, v/v)
and (B) 1 mol/L ammonium acetate/water/acetonitrile (1:20:180,
v/v/v). The initial condition was (A) 90%, and (B) 10%, increasing
linearly to 80% over 3 min. The monitoring ion of VPA was 142.9.
Flow rate was 0.3 mL/min.
An unpaired t-test was used to compare plasma concentrations
of an AED when administered together with a concomitant AED
with plasma concentrations when administered with vehicle only
(signiﬁcance level p < 0.05).3. Results
3.1. Dose selection
All drug effects on ADT were dose-dependent. PER conferred
signiﬁcant changes from the pre-treatment ADT at a dose of
1.5 mg/kg, and LEV, LAM, CBZ, and VPA demonstrated signiﬁcant
effects from doses upwards of 25 mg/kg, 10 mg/kg, 10 mg/kg,
and 200 mg/kg, respectively (Table 1). All changes from
pre-treatment ADT were below 300%. The doses selected
for subsequent analyses were PER 0.75 mg/kg (low dose),
PER 1.5 mg/kg (high dose), LEV 25 mg/kg, LAM 10 mg/kg,
CBZ 10 mg/kg, and VPA 200 mg/kg.
When the 3ADT stimulus was applied, high-dose PER signiﬁ-
cantly reduced seizure score, EEG seizure duration, and motor
seizure duration compared with vehicle alone (p < 0.0001 for all
outcomes; Fig. 1). In contrast, low-dose PER, LEV 50 mg/kg, LAM
20 mg/kg, CBZ 20 mg/kg, or VPA 200 mg/kg did not signiﬁcantly
reduce any of these seizure parameters (Figs. 1 and 2).
3.2. Pharmacodynamic interaction analyses
While individually they had no effect on seizure score or
duration, the combination of low-dose PER with each of the four
AEDs signiﬁcantly reduced all seizure parameters compared with
the respective AED alone. In many cases, there were also signiﬁcant
reductions compared with low-dose PER alone (Fig. 3).
Two-way ANOVA indicated that all interactions were positive
(Table 2). Signiﬁcant interactions were observed in the
parameter of seizure score for PER plus CBZ or VPA, in
the parameter of EEG seizure duration for PER plus VPA, and
in the parameter of motor seizure duration for PER plus LEV,
LAM, CBZ or VPA. On the other hand, non-signiﬁcant interactions
were observed in the parameter of seizure score for PER plus LEV
or LAM and in the parameter of EEG seizure duration for PER
plus LEV, LAM or CBZ.
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Fig. 1. Anti-seizure effect of PER in the 3ADT-stimulus amygdala kindling model: (A)
seizure score; (B) EEG seizure duration; and (C) motor seizure duration (presented
as mean  SEM). ****p < 0.0001 vs vehicle alone. ADT, after-discharge threshold; EEG,
electroencephalography; PER, perampanel; SEM, standard error of the mean.
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Fig. 2. Anti-seizure effect of AEDs in the 3ADT-stimulus amygdala kindling model:
(A) seizure score; (B) EEG seizure duration; and (C) motor seizure duration
(presented as mean  SEM). ADT, after-discharge threshold; AED, antiepileptic drug;
CBZ, carbamazepine; EEG, electroencephalography; LAM, lamotrigine; LEV,
levetiracetam; SEM, standard error of the mean; VPA, valproic acid.
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Individual treatment with low-dose PER, LAM, CBZ, or VPA, but
not LEV, reduced the mean latency time to fall from baseline
(Supplementary Fig. 1). Low-dose PER, CBZ, and VPA each
conferred statistically signiﬁcant reductions of over 50% frombaseline, compared with vehicle alone (vehicle, 0.2% reduction).
Interactions between low-dose PER and each of the other four AEDs
were not statistically signiﬁcant.
Supplementary ﬁgure related to this article can be found, in the
online version, at http://dx.doi.org/10.1016/j.seizure.2014.06.001.
Fig. 3. Anti-seizure effect of low-dose (0.75 mg/kg) and high-dose (1.5 mg/kg) PER in combination with concomitant AEDs in the 3ADT-stimulus amygdala kindling model:
(A) LEV 50 mg/kg; (B) LAM 20 mg/kg; (C) CBZ 20 mg/kg; and (D) VPA 200 mg/kg (presented as mean  SEM). *p < 0.05 vs vehicle plus LEV, LAM, CBZ, or VPA; yp < 0.05 vs vehicle
plus vehicle; zp < 0.05 vs PER 0.75 mg/kg or PER 1.5 mg/kg plus vehicle. CBZ, carbamazepine; EEG, electroencephalography; LAM, lamotrigine; LEV, levetiracetam; PER, perampanel;
SEM, standard error of the mean; VPA, valproic acid.
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Table 2
Statistical analysis of pharmacodynamic interactions between PER and concomitant LEV 50 mg/kg, LAM 20 mg/kg, CBZ 20 mg/kg, or VPA 200 mg/kg (two-way ANOVA;
parametric test used for seizure score, non-parametric test used for EEG seizure duration and motor seizure duration).
Source of variation Seizure score EEG seizure duration Motor seizure duration
Effect p-Value Effect p-Value Effect p-Value
PER alone Signiﬁcant <0.0001 Signiﬁcant <0.0001 Signiﬁcant <0.0001
LEV alone Non-signiﬁcant 0.0811 Non-signiﬁcant 0.0959 Non-signiﬁcant 0.982
Interaction Non-signiﬁcant 0.3391 Non-signiﬁcant 0.5878 Signiﬁcant 0.0017
PER alone Signiﬁcant <0.0001 Signiﬁcant <0.0001 Signiﬁcant <0.0001
LAM alone Signiﬁcant 0.0016 Signiﬁcant 0.0002 Signiﬁcant 0.0003
Interaction Non-signiﬁcant 0.9677 Non-signiﬁcant 0.1057 Signiﬁcant 0.0011
PER alone Signiﬁcant <0.0001 Signiﬁcant 0.0008 Signiﬁcant 0.0012
CBZ alone Signiﬁcant 0.0008 Non-signiﬁcant 0.0522 Signiﬁcant <0.0001
Interaction Signiﬁcant 0.0403 Non-signiﬁcant 0.6773 Signiﬁcant 0.0003
PER alone Signiﬁcant <0.0001 Signiﬁcant <0.0001 Signiﬁcant <0.0001
VPA alone Signiﬁcant <0.0001 Signiﬁcant <0.0001 Signiﬁcant <0.0001
Interaction Signiﬁcant 0.0072 Signiﬁcant <0.0001 Signiﬁcant <0.0001
ANOVA, analysis of variance; CBZ, carbamazepine; EEG, electroencephalography; LAM, lamotrigine; LEV, levetiracetam; PER, perampanel; VPA, valproic acid.
Bold highlights signiﬁcant interactions.
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Administration of low-dose PER did not inﬂuence the plasma
concentrations of concomitant LEV, LAM, CBZ, or VPA (Table 3).
However, the plasma concentration of low-dose PER was
signiﬁcantly increased when co-administered with LEV 50 mg/
kg (+17.2%) or LAM 20 mg/kg (+38.2%), and reduced when
co-administered with CBZ 20 mg/kg (18.2%) or VPA 200 mg/kg
(31.4%).
4. Discussion
The rat amygdala kindling model was used as an appropriate
and clinically relevant approach to assess the effects of PER in
combination with other AEDs. Of note, drug effects in this model
have been shown to be predictive of effects on complex partial
seizures with secondary generalization in humans.13
AED doses were selected that signiﬁcantly elevated the ADT
threshold in the conventional amygdala kindling model, but had no
effect on seizure parameters when a 3-ADT stimulus was applied
to create a condition that would be less sensitive to AEDs.17 This
was intended to simulate the clinical situation, where standard
doses may improve seizure outcomes in patients with epilepsyTable 3
Plasma concentrations of PER and AEDs administered either alone or in combination.
Drug Concomitant AED Mean plasma con
PER 0.75 mg/kg (n = 4) Vehicle 218.0 (8.1) ng/mL
LEV 50 mg/kg 255.4 (15.7) ng/m
LAM 20 mg/kg 301.3 (10.8) ng/m
CBZ 20 mg/kg 178.4 (9.3) ng/mL
VPA 200 mg/kg 149.5 (10.0) ng/m
LEV 50 mg/kg (n = 4) Vehicle 41.9 (1.4) mg/mL 
PER 0.75 mg/kg 40.5 (2.4) mg/mL 
LAM 20 mg/kg (n = 4) Vehicle 10.5 (0.3) mg/mL 
PER 0.75 mg/kg 10.5 (0.5) mg/mL 
CBZ 20 mg/kg (n = 4) Vehicle 6.7 (0.8) mg/mL 
PER 0.75 mg/kg 7.1 (0.3) mg/mL 
VPA 200 mg/kg (n = 4) Vehicle 452.9 (23.8) mg/m
PER 0.75 mg/kg 459.8 (32.9) mg/m
AED, antiepileptic drug; CBZ, carbamazepine; LAM, lamotrigine; LEV, levetiracetam; PE
a p < 0.05 vs drug plus vehicle.(ADT), but have no impact in patients with refractory epilepsy
(3-ADT). In accordance with this model, plasma concentrations of
the AEDs were within the therapeutic range reported in patients
with epilepsy.19 Furthermore, results from the rotarod test
indicated motor impairment with all tested AEDs except for
LEV, supporting sufﬁcient exposure levels to these AEDs.
Although none of the individual AEDs (low-dose PER, LEV, LAM,
CBZ, and VPA) demonstrated efﬁcacy when administered individ-
ually in the 3ADT-stimulus model of refractory epilepsy, low-dose
PER combined with concomitant LEV, LAM, CBZ, or VPA provided
reductions in all seizure parameters. The effects of these
combinations were signiﬁcant compared with the individual
effects of the respective concomitant AEDs, and in many cases
were also signiﬁcant when compared with the individual effects of
low-dose PER.
These observations are consistent with the mechanism of action
of PER complementing the mechanism of action of other currently
available AEDs in refractory epilepsy,9,10 thus supporting its
current indication as an adjunctive treatment for refractory
partial-onset seizures in patients aged 12 years.3,4 In addition,
we suggest that these observations are consistent with the
hypothesis that PER has an effect on both seizure initiation and
propagation, and that PER and these AED combinations may becentration of drug (SEM) Change compared with drug plus vehicle
 –
L +17.2%a
L +38.2%a
 18.2%a
L 31.4%a
–
3.3%
–
0.0
–
+6.0%
L –
L +1.5%
R, perampanel; SEM, standard error of the mean; VPA, valproic acid.
T. Wu et al. / Seizure 23 (2014) 732–739738effective for secondary generalized seizures by inhibiting propa-
gation of seizures from a remote focus. In contrast, phenytoin has
been found to increase the threshold for focal seizures in the rat
amygdala kindling model, but with limited efﬁcacy in reducing the
spread of seizures.20
Statistical analyses indicated positive interactions between
PER and the four concomitant AEDs, which were often
statistically signiﬁcant. However, it is important to note that
previously reported analyses of pooled Phase III data have
indicated that speciﬁc concomitant administration of LEV, LAM
or VPA, vs other concomitant AEDs, has no impact on the efﬁcacy
of adjunctive PER in the treatment of partial-onset seizures in
humans.21 This may be because, as suggested by our experi-
mental results, any pharmacodynamic interactions are not
speciﬁc to individual AEDs, and therefore no difference is
observed between patients receiving one type of concomitant
AED and patients receiving another. Certainly, the use of
polytherapy and the complexity of epilepsy complicate the
evaluation of speciﬁc pharmacodynamic interactions in these
trials. Nonetheless, so far there is no clear evidence of
pharmacodynamic interactions between PER and other AEDs
in patients with epilepsy, and therefore it remains to be
determined whether the interactions observed in the rat
amygdala kindling model translate to the clinical setting.
Since low-dose PER, LAM, CBZ, and VPA all reduced the latency
time to fall in the rotarod test, all were considered to be associated
with some degree of neurotoxicity. However, although concomi-
tant administration of low-dose PER conferred an additional
latency reduction, beyond that observed with LAM, CBZ, or VPA
when administered individually, this interaction was not statisti-
cally signiﬁcant. Overall, the data suggest that adjunctive PER may
not be associated with speciﬁc neurotoxicity interactions with
AEDs with other mechanisms of action.
PER is metabolized by CYP3A4/5 isoenzymes, meaning that its
clearance is increased, and plasma concentrations are reduced, in
the presence of enzyme-inducing AEDs such as CBZ, oxcarbazepine
and phenytoin.8,22,23 In the present study, the plasma concentra-
tion of PER was reduced in the presence of CBZ, and also in the
presence of VPA, suggesting that any pharmacodynamic interac-
tions were potentially underestimated. In contrast, the plasma
concentration of PER was increased by 17.2% when administered in
combination with LEV, and by 38.2% in combination with LAM. Of
note, the efﬁcacy of the combination of PER and LAM was
comparable or even superior to high-dose PER, indicating that a
positive pharmacodynamic interaction may exist.
Some seizure models provide reduced sensitivity to some AEDs,
but not others, which can be useful in some experimental
settings.24 In addition, isobolography is often used to evaluate
speciﬁc pharmacodynamic interactions across a dose range25 and
can be applied in the amygdala kindling model.26 However, the
approach used in this study was selected to produce resistance to a
range of AEDs at clinically relevant doses,19 which conferred
behavioral neurotoxicity, so that multiple interactions could be
evaluated and, therefore, it was considered unlikely that this
approach would overestimate any ﬁndings.
5. Conclusion
These data from a rat amygdala kindling model support the
efﬁcacy of PER as adjunctive therapy for the treatment of refractory
partial-onset seizures when used in combination with LEV, LAM,
CBZ, or VPA. Interestingly, they also indicate positive and
signiﬁcantly positive effects of adjunctive PER on seizure severity
parameters, without showing speciﬁc interactions with any of the
individual AEDs in particular. However, these ﬁndings are yet to be
conﬁrmed in a clinical population, where the assessment ofpharmacodynamic interactions is complicated by polytherapy and
the complexity of epilepsy.
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